|View printer-friendly version|
Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
SB 11285 Shows Potent and Highly-Durable Anti-Tumor Activity in Several Tumor Models
“Data from multiple tumor models in preclinical studies of SB 11285 demonstrated durable antitumor activity and support continued development of SB 11285, either alone or in combination with other agents, with different routes of administration,” said Radhakrishnan (
SB 11285 was evaluated in several syngeneic mouse models, including A20 lymphoma, CT26 colon carcinoma, B16 melanoma, and orthotopic 4T1 breast cancer models, for tumor growth inhibition (TGI) and tumor growth delay (TGD). SB 11285 was administered by intravenous (i.v.), intraperitoneal (i.p.), and intra-tumoral (i.t.) routes. The results are summarized here:
The anti-tumor activity observed in these models correlated with anti-tumoral immune response. Immuno-histochemistry combined with flow cytometric analysis of tissues and blood from SB 11285-treated groups revealed the presence of activated immune cells, including CD8+ T cells, natural killer (NK) cells and macrophages critical for anti-tumor effects.
A copy of the poster made during the presentation will be included on the Spring Bank Pharmaceuticals website at www.springbankpharm.com/publications.
Source: Spring Bank Pharmaceuticals Inc.